Beyond Traffic Chasing: How ArkJianke Validated Its 'AI + Chronic Care' Model with 30% Revenue Surge and Path to Profitability

In recent years, China’s healthcare industry has been undergoing a profound paradigm shift, gradually moving from extensive scale expansion to intensive value cultivation. At this critical juncture of transformation, Fangzhou Pharmaceutical (06086.HK), with its robust financial performance, has taken the lead in validating the strong certainty and growth potential released to the market by its chronic disease management model centered on the “acquaintance-based” trust relationship between doctors and patients.

Recently, Fangzhou Pharmaceutical released its positive profit forecast for 2025. The data shows that the company expects full-year revenue to reach RMB 3.5–3.55 billion, representing a year-on-year increase of approximately 30%. This revenue scale surpasses the previous institutional forecast of HKD 3.5 billion (approximately RMB 3.13 billion). On the profit front, following the achievement of adjusted profitability in 2024, the company is projected to report a net profit of RMB 7–10 million in 2025, thereby achieving overall profitability.

Its high-quality performance growth serves as a concentrated validation of the business model value built on “familiar doctor-patient” relationships. This not only provides a solid basis for the market to reassess its intrinsic value, but also strongly supports the underlying logic driving the stock price upward.

As 2026 began, medical AI once again surged in popularity. Fangzhou Pharmaceutical, which pioneered the integration of “AI + chronic disease services” and achieved a critical leap in “AI + H2H (Hospital to Home)” in 2025, has demonstrated clear leadership in the medical AI sector by securing an early advantageous position in the race to build a “Chinese version of OpenEvidence.” Amid the industry’s pursuit of high-quality development, Fangzhou Pharmaceutical’s explorations and practices have become a key benchmark for observing the future value trajectory of internet healthcare.

If financial data serves as a health checkup report for a company, then Fangzhou Pharmaceutical’s “2025 Performance Report” undoubtedly demonstrates a robust physique. A 30% revenue growth rate is already commendable in the fiercely competitive landscape of the internet healthcare sector, where competition revolves around existing market share. Furthermore, the achievement of “dual profitability” further underscores the solid profit foundation and sustainable growth potential of its business model.

In fact, before Fangzhou Pharmaceutical’s performance breakthrough drew market attention, certain investment institutions had already detected its value signals.

Looking back to mid-2025, Citi Research initiated coverage of Fangzhou Pharmaceutical with a “Buy” rating and set a target price of HK$8.5, implying significant upside potential from the then-current share price. At that time, Citi’s bullish thesis was primarily underpinned by the rising penetration rate of chronic disease management services and improvements in operational efficiency.

Moreover, in its in-depth research report released in January 2026, Gelonghui Research Institute projected that the company’s revenue would reach HK$3.5 billion in 2025 and HK$4.8 billion in 2026, noting that Fangzhou Pharmaceutical is entering a golden phase of value revaluation.

Today, this earnings forecast, which demonstrates strong growth, is essentially a release of the endogenous strength accumulated by Fangzhou Pharmaceutical. It also reveals to the market that such robust and profound sustainable operational capability is precisely the fundamental reason why professional institutions such as Citigroup and Gelonghui had previously firmly assigned it high ratings and maintained a bullish outlook.

Fangzhou Pharmaceutical’s ecosystem strength has already translated into financial performance, yet its current valuation remains undervalued. Based on the 2025 revenue forecast in institutional research reports, its price-to-sales (P/S) ratio is only around 0.8x, and the P/S ratio based on the 2026 revenue forecast is 0.6x. In contrast, the industry averages are 4.9x and 4.1x, respectively.

Fangzhou Pharmaceutical is clearly an undervalued gem. This significant valuation discount largely stems from the market’s insufficient recognition of the “service value,” “user stickiness,” and “high repurchase logic” created by its “acquaintance-based doctor-patient” model. However, in a market environment that prioritizes certain returns, this has left a substantial margin of safety for long-term investors.

If the performance exceeding institutional expectations is the “effect,” then Fangzhou Pharmaceutical’s deep cultivation of its “H2H Smart Healthcare Ecosystem,” built on the foundation of the “familiar doctor-patient” model, is the “cause.” In the fiercely competitive internet healthcare sector characterized by stock competition, why has Fangzhou Pharmaceutical demonstrated such operational resilience? The answer lies in its relentless pursuit of the “familiar doctor-patient” model and the “deterministic” business closed loop established thereby.

Unlike models that chase single-visit patient volume or broad user growth, the essence of chronic disease management lies in long-termism. Its core is to establish strong trust relationships to ensure patients’ continuity and adherence to chronic care services. Patients with chronic conditions have a stronger emotional reliance on “being understood and receiving long-term companionship.” This reliance pertains not only to health itself but also to their sense of security in daily life.

Fangzhou Pharmaceutical’s business logic is built precisely on this insight, with its platform focused on empowering the long-term relationships between doctors and patients. This “acquaintance-based” doctor-patient connection, established through genuine offline clinical consultations, creates a high-trust environment for subsequent follow-up visits, consultations, and health management.

This profound trust translates directly into highly resilient business metrics. Although the latest user data was not disclosed in this earnings forecast, the high-stickiness characteristic inherent to its business model has been repeatedly validated by previously released figures. For instance, an 85% repurchase rate among paying users and prescription drug transactions accounting for over 80% of total GMV have become stable features of its business model. These figures are not accidental outcomes of traffic fluctuations, but rather an inevitable reflection of patients’ deep reliance and sustained demand release under the “familiar doctor-patient” model, forming a solid foundation for continuous performance growth.

From a business perspective, this “acquaintance-based doctor-patient” model creates multiple barriers: first, it establishes user relationships with high switching costs, as patients are unlikely to easily switch platforms that have been tracking their conditions over the long term; second, trust-based long-term health management services offer greater value than one-off transactions; ultimately, it generates stable revenue streams based on long-term medication and management.

Broad market prospects are injecting long-term momentum into this model. Data from Frost & Sullivan shows that China’s chronic disease management market is projected to exceed RMB 600 billion by 2030. Amid the trends of population aging and high prevalence of chronic diseases, platforms capable of providing comprehensive, trustworthy management services for patients are seeing their value increasingly highlighted.

Fangzhou Pharmaceutical has established a sufficiently deep business moat through its “acquaintance-based doctor-patient” model. However, judging from a series of moves made last year, the company has set its sights further ahead: by leveraging cutting-edge AI technology, it aims not only to consolidate its existing advantages but also to pioneer an entirely new dimension of growth for the future. This forward-looking strategic layout also aligns with the national call for intelligent upgrades across the industry.

In 2025, policy frameworks charted a course for the deep integration of “AI + Healthcare.” In August, the State Council issued the *Opinions on Deepening the Implementation of the “Artificial Intelligence Plus” Action*, explicitly designating assisted diagnosis and treatment, as well as health management, as key application scenarios. Subsequently, in November of the same year, the National Health Commission released the *Implementation Opinions on Promoting and Regulating the Development of “Artificial Intelligence Plus Healthcare” Applications*, clearly proposing to leverage next-generation artificial intelligence to deeply empower the high-quality development of the healthcare sector.

Fangzhou Pharmaceutical’s AI strategy is not a mere pursuit of trendy concepts, but rather a strategic elevation and efficiency revolution of its core “acquaintance-based doctor-patient” model. From a business logic perspective, the integration of AI provides “intelligent empowerment” to existing “relationship connections.” By leveraging AI technology, the company further enhances service efficiency and delivers higher-quality, more personalized services to patients, thereby strengthening the value of the entire trust chain and driving further growth in user lifetime value.

Therefore, Fangzhou Pharmaceutical’s AI narrative is not an isolated technological chapter, but a dual-track story of “continuous enhancement of core business” and “early locking-in of future growth tracks.”

One case indirectly highlights the forward-looking nature of this company’s strategic layout. As major tech giants scrambled to benchmark their offerings against the overseas product OpenEvidence at the start of 2026, Fangzhou Pharmaceutical had already secured its position in this sector by September 2025, leveraging its profound understanding of business scenarios. Moreover, unlike OpenEvidence, which relies on Western literature, Fangzhou Pharmaceutical is deeply adapted to China’s local diagnostic and treatment standards and guidelines. This deep localization based on a domestic knowledge system has formed its unique core competitive advantage.

Examining Fangzhou Pharmaceutical’s development trajectory, its rapid growth in 2025 was not an isolated financial milestone, but rather the natural outcome of its longstanding strategic focus and business model construction. It clearly demonstrates an upward trajectory from “validating the logic” to “unlocking value.”

The rapid growth in performance and the market’s perception gap constitute the most significant investment tension at present. The company’s revenue growth, which has exceeded expectations, validates the resilience and potential of its business model. However, the substantial valuation discount relative to the industry average clearly reveals that the market still lags in recognizing its intrinsic value, particularly the value created by the “acquaintance-based doctor-patient” model.

This current state of “financials already realized” versus “valuation not yet aligned” precisely provides a clear starting point and room for value reassessment. As the pendulum of value reassessment begins to swing, the valuation trough for companies that combine solid financial foundations with technological reserves is likely to be only temporary.

(This article is based on the analysis of publicly available information, intended for informational reference only and does not constitute any investment advice.)